Imatinib in long term treatment of Chronic Myeloid Leukemia

Researchers from Imperial College London have published data on long term (5 yr) treatment of Chronic Myeloid Leukemia (CML) patients with Imatinib. At 5 years estimated overall survival and PFS were 83.2% and 82.7%, respectively.

Santen license rights to MacuSights sirolimus

Santen have licensed rights to develop and commercialize MacuSights Sirolimus for ocular diseases and conditions in Japan and Asia.

Addition of mTor inhibitor rapamycin alters tumor metabolism in glioblastoma cells

Researchers at UCLA have published data showing that rapamycin addition to glioblastoma cells alters tumor cell metabolism

Phase II data on lapatinib (Tykerb) presented at ASCO

Data presented at ASCO highlight recent findings with lapatinib including:
- Phase II data on Lapatinib in combination with pazopanib demonstrates activity in first-line HER2 positive breast cancer
- Phase II data on Lapatinib in combination with bevacizumab shows efficacy in recurrent metastatic HER2 positive breast cancer
– Monotherapy for relapsed inflammatory breast cancer shows [...]

Phase II data show GSK’s pazopanib to demonstrate efficacy in NSCLC and renal cancer

Phase II data presented at ASCO show GSK’s multikinase inhibitor pazopanib to demonstrate efficacy as a single agent treatment in non-small cell lung cancer (NSCLC) and advanced renal cell cancer

Phase II data on Exelixis EGFR/HER2/VEGFR2 inhibitor XL647

Phase II data presented at ASCO show Exelixis’ EGFR/HER2/VEGFR2 inhibitor XL647 to demonstrate efficacy in non-small cell lung cancer (NSCLC)

Incyte’s JAK inhibitor INCB18424 shows efficacy in treating Myelofibrosis symptoms

Phase I/II data presented at ASCO show Incyte’s JAK inhibitor INCB18424 reduced fatigue, night sweats and pruritus, and increased appetite and weight gain in myelofibrosis patients

Phase I data on YM BioSciences EGF MAb nimotuzumab for NSCLC

Phase I data presented at ASCO show YM BioSciences EGF MAb nimotuzumab to exhibit efficacy in the treatment< of non-small cell lung cancer (NSCLC). Median survival obtained was 60 weeks

Nexavar clinical data presented at ASCO

Lung cancer – Phase II results show ‘encouraging’ results in heavily pre-treated patients. Nexavar continuation resulted in longer periods of disease control
Thyroid Cancer -Phase II results show Nexavar displayed anti-tumor activity in the majority of patients
GIST – Phase II results show that Nexavar is active and well tolerated in patients with Gleevec or Gleevec [...]

Novartis mTor inhibitor RAD001 (everolimus) shows efficacy in breast cancer

Phase II data presented at ASCO show Novartis’ mTor inhibitor RAD001 significantly increased efficacy of letrozole in patients with newly diagnosed hormone-positive breast cancer. Phase I data presented also showed that RAD001 has potential in overcoming Herceptin resistance